A Clinical Research of Taerolimus (prograf) in the Prevention of Renal Allograft Rejection:A Report of 136 Cases

于立新,付绍杰,马俊杰,徐健,杜传福,邓文锋,王亦斌,祖强
DOI: https://doi.org/10.3760/cma.j.issn.0254-1785.2000.06.015
2000-01-01
Abstract:Objective To study the effects and side effects of tacrolimus (FK506) in the prevention of renal allograft rejection. Methods 136 patients undergoing renal transplantion orally administered FK506 with the initial dose of 0.15 ?mg/kg daily, mycophenolate mofetil ( 1.0 ?g/d) and meticorten (Pred, 30?mg/d) 24?h after transplantation. The curative effects, therapy index and side effects were observed. Results In 136 patients using FK506 after renal transplantation the incidence of acute rejection (AR) was 12.5 ?% ( n =17), glycometabolism disorder was 18.4 ?%( n =15), nervous system disturbance was 2.2 ?%( n =3), abnormal liver function was 3.7 ( n =5), nephrotoxicity was 2.9 ?% ( n =4), disorders of digestion was 22.8 ?%( n =31), cytomegalovirus (CMV) infection was 3.7 ?%( n =5), pulmonary infection was 2.2 ?%( n =3). One died from cerebral hemorrhage but the allograft function was normal and two were removed the allograft because of the function loss. All the blood concentrations of FK506 were 5 to 20?μg/L. Conclusions FK506 could decrease the incidence of rejection in kidney transplant recipients with little side effects and toxicity. So it was a safe and effective immunosuppressive agent, particularly in patients who experienced cyclosporine nephrotoxicity. However, glycometabolism disorder caused by FK506 should be paid attention.
What problem does this paper attempt to address?